The clinical utility of the Revised European-American Lymphoma (R.E.A.L.) Classification: Preliminary results of a prospective study in patients with non-Hodgkin's lymphoma from a single centre

J. W. Sweetenham, P. F.M. Smartt, B. S. Wilkins, J. C. Pellatt, J. L. Smith, A. Ramsay, J. M.A. Whitehouse

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: The clinical applicability of the Revised European-american Lymphoma (R.E.A.L) Classification has been demonstrated in several retrospective studies. The present, ongoing study was initiated to evaluate the clinical and pathological utility of the R.E.A.L. Classification compared with the Working Formulation (WF) in a prospective fashion, in an unselected patient population treated at a single institution. Patients and methods: Prospective data were collected on 596 biopsics from 557 patients referred with an initial diagnosis of lymphoma. After initial histologic review, 465 biopsies from 441 patients were confirmed as non-Hodgkin's lyphoma (NHL), 412 of which could be classified in R.E.A.L. and WF. Results: According to WF criteria, 25% were low grade, 58% intermediate grade and 2% high grade. 14% could not be allocated to a WF subtype. According to R.E.A.L., 46% were diffuse large B cell, 19% follicle centre lymphoma, 6% marginal zone, 6% small lymphocytic, 4% mantle cell, and 3% T-cell anaplastic large cell. For those with B-cell NHL, 7% were unclassifiable in WF compared with 1% in R.E.A.L. Corresponding figures for T-cell NHL were 68% and 3%, respectively. Conclusions: Preliminary results confirm the clinical utility of the R.E.A.L. Classification in a single institution setting, demonstrating that cases were more readily sub-typed in R.E.A.L. compared with WF. Frequencies are comparable with I.L.S.G. data. Further follow up with large patient numbers is on-going to analyse survival data with reference to clinical prognostic factors.

Original languageEnglish (US)
Pages (from-to)1121-1124
Number of pages4
JournalAnnals of Oncology
Volume10
Issue number9
DOIs
StatePublished - Oct 25 1999
Externally publishedYes

Fingerprint

Non-Hodgkin's Lymphoma
Lymphoma
Prospective Studies
B-Lymphocytes
T-Lymphocytes
Survival Analysis
Retrospective Studies
Biopsy
Population

Keywords

  • Classification
  • Lymphom
  • Non-hodgkin's
  • R.E.A.L

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

The clinical utility of the Revised European-American Lymphoma (R.E.A.L.) Classification : Preliminary results of a prospective study in patients with non-Hodgkin's lymphoma from a single centre. / Sweetenham, J. W.; Smartt, P. F.M.; Wilkins, B. S.; Pellatt, J. C.; Smith, J. L.; Ramsay, A.; Whitehouse, J. M.A.

In: Annals of Oncology, Vol. 10, No. 9, 25.10.1999, p. 1121-1124.

Research output: Contribution to journalArticle

@article{53d9bb5ea4f44d219c183f388f1b955c,
title = "The clinical utility of the Revised European-American Lymphoma (R.E.A.L.) Classification: Preliminary results of a prospective study in patients with non-Hodgkin's lymphoma from a single centre",
abstract = "Background: The clinical applicability of the Revised European-american Lymphoma (R.E.A.L) Classification has been demonstrated in several retrospective studies. The present, ongoing study was initiated to evaluate the clinical and pathological utility of the R.E.A.L. Classification compared with the Working Formulation (WF) in a prospective fashion, in an unselected patient population treated at a single institution. Patients and methods: Prospective data were collected on 596 biopsics from 557 patients referred with an initial diagnosis of lymphoma. After initial histologic review, 465 biopsies from 441 patients were confirmed as non-Hodgkin's lyphoma (NHL), 412 of which could be classified in R.E.A.L. and WF. Results: According to WF criteria, 25{\%} were low grade, 58{\%} intermediate grade and 2{\%} high grade. 14{\%} could not be allocated to a WF subtype. According to R.E.A.L., 46{\%} were diffuse large B cell, 19{\%} follicle centre lymphoma, 6{\%} marginal zone, 6{\%} small lymphocytic, 4{\%} mantle cell, and 3{\%} T-cell anaplastic large cell. For those with B-cell NHL, 7{\%} were unclassifiable in WF compared with 1{\%} in R.E.A.L. Corresponding figures for T-cell NHL were 68{\%} and 3{\%}, respectively. Conclusions: Preliminary results confirm the clinical utility of the R.E.A.L. Classification in a single institution setting, demonstrating that cases were more readily sub-typed in R.E.A.L. compared with WF. Frequencies are comparable with I.L.S.G. data. Further follow up with large patient numbers is on-going to analyse survival data with reference to clinical prognostic factors.",
keywords = "Classification, Lymphom, Non-hodgkin's, R.E.A.L",
author = "Sweetenham, {J. W.} and Smartt, {P. F.M.} and Wilkins, {B. S.} and Pellatt, {J. C.} and Smith, {J. L.} and A. Ramsay and Whitehouse, {J. M.A.}",
year = "1999",
month = "10",
day = "25",
doi = "10.1023/A:1008354517385",
language = "English (US)",
volume = "10",
pages = "1121--1124",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - The clinical utility of the Revised European-American Lymphoma (R.E.A.L.) Classification

T2 - Preliminary results of a prospective study in patients with non-Hodgkin's lymphoma from a single centre

AU - Sweetenham, J. W.

AU - Smartt, P. F.M.

AU - Wilkins, B. S.

AU - Pellatt, J. C.

AU - Smith, J. L.

AU - Ramsay, A.

AU - Whitehouse, J. M.A.

PY - 1999/10/25

Y1 - 1999/10/25

N2 - Background: The clinical applicability of the Revised European-american Lymphoma (R.E.A.L) Classification has been demonstrated in several retrospective studies. The present, ongoing study was initiated to evaluate the clinical and pathological utility of the R.E.A.L. Classification compared with the Working Formulation (WF) in a prospective fashion, in an unselected patient population treated at a single institution. Patients and methods: Prospective data were collected on 596 biopsics from 557 patients referred with an initial diagnosis of lymphoma. After initial histologic review, 465 biopsies from 441 patients were confirmed as non-Hodgkin's lyphoma (NHL), 412 of which could be classified in R.E.A.L. and WF. Results: According to WF criteria, 25% were low grade, 58% intermediate grade and 2% high grade. 14% could not be allocated to a WF subtype. According to R.E.A.L., 46% were diffuse large B cell, 19% follicle centre lymphoma, 6% marginal zone, 6% small lymphocytic, 4% mantle cell, and 3% T-cell anaplastic large cell. For those with B-cell NHL, 7% were unclassifiable in WF compared with 1% in R.E.A.L. Corresponding figures for T-cell NHL were 68% and 3%, respectively. Conclusions: Preliminary results confirm the clinical utility of the R.E.A.L. Classification in a single institution setting, demonstrating that cases were more readily sub-typed in R.E.A.L. compared with WF. Frequencies are comparable with I.L.S.G. data. Further follow up with large patient numbers is on-going to analyse survival data with reference to clinical prognostic factors.

AB - Background: The clinical applicability of the Revised European-american Lymphoma (R.E.A.L) Classification has been demonstrated in several retrospective studies. The present, ongoing study was initiated to evaluate the clinical and pathological utility of the R.E.A.L. Classification compared with the Working Formulation (WF) in a prospective fashion, in an unselected patient population treated at a single institution. Patients and methods: Prospective data were collected on 596 biopsics from 557 patients referred with an initial diagnosis of lymphoma. After initial histologic review, 465 biopsies from 441 patients were confirmed as non-Hodgkin's lyphoma (NHL), 412 of which could be classified in R.E.A.L. and WF. Results: According to WF criteria, 25% were low grade, 58% intermediate grade and 2% high grade. 14% could not be allocated to a WF subtype. According to R.E.A.L., 46% were diffuse large B cell, 19% follicle centre lymphoma, 6% marginal zone, 6% small lymphocytic, 4% mantle cell, and 3% T-cell anaplastic large cell. For those with B-cell NHL, 7% were unclassifiable in WF compared with 1% in R.E.A.L. Corresponding figures for T-cell NHL were 68% and 3%, respectively. Conclusions: Preliminary results confirm the clinical utility of the R.E.A.L. Classification in a single institution setting, demonstrating that cases were more readily sub-typed in R.E.A.L. compared with WF. Frequencies are comparable with I.L.S.G. data. Further follow up with large patient numbers is on-going to analyse survival data with reference to clinical prognostic factors.

KW - Classification

KW - Lymphom

KW - Non-hodgkin's

KW - R.E.A.L

UR - http://www.scopus.com/inward/record.url?scp=0032820064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032820064&partnerID=8YFLogxK

U2 - 10.1023/A:1008354517385

DO - 10.1023/A:1008354517385

M3 - Article

C2 - 10572614

AN - SCOPUS:0032820064

VL - 10

SP - 1121

EP - 1124

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 9

ER -